Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors
US10144737B2 · kind B2 · utility
2Cited by
0References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 20, 2014 |
| Grant date | Dec 4, 2018 |
| Priority date | — |
| Expiry date | Dec 12, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D473/34
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.